C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance

Füst, George; Miszlay, Z; Czink, Elena; Varga, Lilian; Pálóczi, Katalin; Szegedi, G; Hollán, Susan R.

doi:10.1016/0165-2478(87)90110-6

Cited by 27 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complement C3 in osteoma patient serum was quite different when compared with normal serum. The results were consistent with earlier observations in literatures [36][37][38][39][40][41][42][43][44][45][46] and are promising regarding the practical use of the method. Attempts to develop this method in clinical analysis and in bioanalysis research will be undertaken in a further study.…”

Section: Application To Serum Samples From Healthy Donors and Sacrum supporting

confidence: 92%

“…Complement C3 plays a key role in immunity and is of great diagnostic importance [34]. It was reported that in serum of cancer patients, various types of complements including complement C3 are found; abnormal, elevated, or decreased values were observed in patients bearing a tumor [36][37][38][39][40][41][42][43][44][45][46]. Sera from healthy donors and sacrum osteoma patients obtained from the Beijing Jishuitan Hospital were examined to investigate the feasibility of the presently proposed method in the study of serum complement C3.…”

Section: Application To Serum Samples From Healthy Donors and Sacrum mentioning

confidence: 99%

See 1 more Smart Citation

A novel probe for chemiluminescent image detection of proteins in two‐dimensional gel electrophoresis

Liu¹,

Ouyang²,

Baeyens³

et al. 2008

Electrophoresis

View full text Add to dashboard Cite

Carrier ampholytes were found to enhance the chemiluminescence (CL) emission from the 3-aminophthalic hydrazide (luminol)-hydrogen peroxide system. They can be used as a chemiluminescent probe for rapid detection of major proteins in gels. This probe attracted much interest due to its ability to attach proteins, and to the possibility to combine it with separation techniques generating the CL emission directly. Increased signal intensity was achieved employing optimized concentrations of the carrier ampholyte enhancer. The binding of carrier ampholyte to proteins was found to occur at the pI of the proteins. Proteins from different regions of the gels were identified by their matrix-assisted TOF mass spectra and by appropriate database search, the results illustrating the possibility of major protein detection in human serum. Direct CL image detection with the carrier ampholyte probe can be applied for the detection of characteristic proteins in patients, i.e., proteins which cannot be detected without the probe.

show abstract

Section: Application To Serum Samples From Healthy Donors and Sacrum supporting

confidence: 92%

Section: Application To Serum Samples From Healthy Donors and Sacrum mentioning

confidence: 99%

A novel probe for chemiluminescent image detection of proteins in two‐dimensional gel electrophoresis

Liu¹,

Ouyang²,

Baeyens³

et al. 2008

Electrophoresis

View full text Add to dashboard Cite

show abstract

“…Higher complement hemolytic activity and C3 levels have been observed in serum samples from children with neuroblastoma (Carli et al 1979) and elevated complement levels have similarly been reported in patients with carcinomas of the digestive tract (Maness and Orengo 1977) or with brain tumors (Matsutani et al 1984). In vivo alterations in the activation of the classical pathway have been described in patients with chronic lymphatic leukemia (Fust et al 1987 ; Schlesinger et al 1996), with a strong positive correlation between survival and the initial activity of the classical pathway of complement (Varga et al 1995). …”

Section: 3 Complement In Immune Surveillance Against Tumorsmentioning

confidence: 99%

The Role of Complement in Tumor Growth

Pı́o

Corrales

Lambris

2013

Advances in Experimental Medicine and Biology

173

159

View full text Add to dashboard Cite

Complement is a central part of the immune system that has developed as a first defense against non-self cells. Neoplastic transformation is accompanied by an increased capacity of the malignant cells to activate complement. In fact, clinical data demonstrate complement activation in cancer patients. On the basis of the use of protective mechanisms by malignant cells, complement activation has traditionally been considered part of the body's immunosurveillance against cancer. Inhibitory mechanisms of complement activation allow cancer cells to escape from complement-mediated elimination and hamper the clinical efficacy of monoclonal antibody–based cancer immunotherapies. To overcome this limitation, many strategies have been developed with the goal of improving complement-mediated effector mechanisms. However, significant work in recent years has identified new and surprising roles for complement activation within the tumor microenvironment. Recent reports suggest that complement elements can promote tumor growth in the context of chronic inflammation. This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer.

show abstract

“…Lucas et al [21] have suggested that a tumor-specific immune response occurs in papillary thyroid carcinomas, with activation of the classical complement cascade. Follicular and MALT lymphomas also deposit elements of the classical pathway [23], and alterations in this pathway have been described in patients with chronic lymphocytic leukemia [37, 38]. In contrast, the results of other studies have suggested that lymphoma and myeloma cells activate the alternative pathway [19, 39–41].…”

Section: Complement Activation In Cancer Cellsmentioning

confidence: 99%

Complement inhibition in cancer therapy

Pı́o

Ajona²,

Lambris

2013

Seminars in Immunology

118

View full text Add to dashboard Cite

For decades, complement has been recognized as an effector arm of the immune system that contributes to the destruction of tumor cells. In fact, many therapeutic strategies have been proposed that are based on the intensification of complement-mediated responses against tumors. However, recent studies have challenged this paradigm by demonstrating a tumor-promoting role for complement. Cancer cells seem to be able to establish a convenient balance between complement activation and inhibition, taking advantage of complement initiation without suffering its deleterious effects. Complement activation may support chronic inflammation, promote an immunosuppressive microenvironment, induce angiogenesis, and activate cancer-related signaling pathways. In this context, inhibition of complement activation would be a therapeutic option for treating cancer. This concept is relatively novel and deserves closer attention. In this paper, we will summarize the mechanisms of complement activation on cancer cells, the cancer-promoting effect of complement initiation, and the rationale behind the use of complement inhibition as a therapeutic strategy against cancer.

show abstract

C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance

Cited by 27 publications

References 11 publications

A novel probe for chemiluminescent image detection of proteins in two‐dimensional gel electrophoresis

A novel probe for chemiluminescent image detection of proteins in two‐dimensional gel electrophoresis

The Role of Complement in Tumor Growth

Complement inhibition in cancer therapy

Contact Info

Product

Resources

About